|
1
|
Ferreri AJM, Calimeri T, Cwynarski K,
Dietrich J, Grommes C, Hoang-Xuan K, Hu LS, Illerhaus G, Nayak L,
Ponzoni M and Batchelor TT: Primary central nervous system
lymphoma. Nat Rev Dis Primers. 9:292023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Soussain C, Choquet S, Blonski M, Leclercq
D, Houillier C, Rezai K, Bijou F, Houot R, Boyle E, Gressin R, et
al: Ibrutinib monotherapy for relapse or refractory primary CNS
lymphoma and primary vitreoretinal lymphoma: Final analysis of the
phase II ‘proof-of-concept’ iLOC study by the Lymphoma study
association (LYSA) and the French oculo-cerebral lymphoma (LOC)
network. Eur J Cancer. 117:121–130. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schaff LR and Grommes C: Primary central
nervous system lymphoma. Blood. 140:971–979. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Abrey LE, Batchelor TT, Ferreri AJ,
Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A,
Soussain C, DeAngelis LM, et al: Report of an international
workshop to standardize baseline evaluation and response criteria
for primary CNS lymphoma. J Clin Oncol. 23:5034–5043. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
de Koning ME, Hof JJ, Jansen C, Doorduijn
JK, Bromberg JEC and van der Meulen M: Primary central nervous
system lymphoma. J Neurol. 27:2906–2913. 2024. View Article : Google Scholar
|
|
6
|
Grommes C and DeAngelis LM: Primary CNS
lymphoma. J Clin Oncol. 35:2410–2418. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Langner-Lemercier S, Houillier C, Soussain
C, Ghesquières H, Chinot O, Taillandier L, Soubeyran P, Lamy T,
Morschhauser F, Benouaich-Amiel A, et al: Primary CNS lymphoma at
first relapse/progression: Characteristics, management, and outcome
of 256 patients from the French LOC network. Neuro Oncol.
18:1297–1303. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rancea M, Will A, Borchmann P, Monsef I,
Engert A and Skoetz N: Fifteenth biannual report of the Cochrane
Haematological Malignancies Group-focus on non-Hodgkin's lymphoma.
J Natl Cancer Inst. 105:1159–1170. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rubenstein JL, Combs D, Rosenberg J, Levy
A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, et al:
Rituximab therapy for CNS lymphomas: Targeting the leptomeningeal
compartment. Blood. 101:466–468. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
van der Meulen M, Dirven L, Habets EJJ,
Bakunina K, Smits M, Achterberg HC, Seute T, Cull G, Schouten H,
Zijlstra JM, et al: Neurocognitive functioning and radiologic
changes in primary CNS lymphoma patients: Results from the HOVON
105/ALLG NHL 24 randomized controlled trial. Neuro Oncol.
23:1315–1326. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ferreri AJM, Cwynarski K, Pulczynski E,
Fox CP, Schorb E, Celico C, Falautano M, Nonis A, La Rosée P,
Binder M, et al: Long-term efficacy, safety and neurotolerability
of MATRix regimen followed by autologous transplant in primary CNS
lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia.
36:1870–1878. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Therkelsen KE, Schaff LR, Nandakumar S,
Omuro AMP, DeAngelis LM and Grommes C: Long-term outcomes in
primary CNS lymphoma after R-MVP and High-dose chemotherapy with
autologous hematopoietic stem cell transplant. Neurology.
101:e710–e716. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hoang-Xuan K, Deckert M, Ferreri AJM,
Furtner J, Gallego Perez-Larraya J, Henriksson R, Hottinger AF,
Kasenda B, Lefranc F, Lossos A, et al: European Association of
Neuro Oncology (EANO) guidelines for treatment of primary central
nervous system lymphoma (PCNSL). Neuro Oncol. 25:37–53. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schmitt AM, Herbrand AK, Fox CP, Bakunina
K, Bromberg JEC, Cwynarski K, Doorduijn JK, Ferreri AJM, Illerhaus
G, Issa S, et al: Rituximab in primary central nervous system
lymphoma-A systematic review and meta-analysis. Hematol Oncol.
37:548–557. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zorzela L, Loke YK, Ioannidis JP, Golder
S, Santaguida P, Altman DG, Moher D and Vohra S; PRISMAHarms Group,
: PRISMA harms checklist: Improving harms reporting in systematic
reviews. BMJ. 352:i1572016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Frandsen TF, Moos C, Marino C and Eriksen
MB: Supplementary databases increased literature search coverage
beyond PubMed and Embase. J Clin Epidemiol. 181:1117042025.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao S, Lu Z, Zhao F, Tang S, Zhang L and
Feng C: Assessing the impact of probiotics on immunotherapy
effectiveness and antibiotic-mediated resistance in cancer: A
systematic review and meta-analysis. Front Immunol. 16:15389692025.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tierney JF, Stewart LA, Ghersi D, Burdett
S and Sydes MR: Practical methods for incorporating summary
time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dina S, Xu XP, Chen BB, Chen T, Li P, Ding
TL, Ma L, Yuan Y, Lin ZG and Wang G: The therapeutic effect of
high-dose methotrexate (HD-MTX) with rituximab in newly diagnosed
primary central nervous system lymphoma (PCNSL). Fudan Univ J Med
Sci. 46:14–22. 2019.
|
|
20
|
Higgins JP, Altman DG, Gøtzsche PC, Jüni
P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, et
al: The Cochrane Collaboration's tool for assessing risk of bias in
randomised trials. BMJ. 343:d59282011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stang A: Critical evaluation of the
Newcastle-Ottawa scale for the assessment of the quality of
nonrandomized studies in meta-analyses. Eur J Epidemiol.
25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Debray TP, Damen JA, Snell KI, Ensor J,
Hooft L, Reitsma JB, Riley RD and Moons KG: A guide to systematic
review and meta-analysis of prediction model performance. BMJ.
356:i64602017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Curry LD, Munker R, Li N, Yan D, Pryor P,
Nozad S, Keller P, Monohan GP, Iragavarapu C and Krem MM:
Performance status, comorbidities, and cycles of methotrexate exert
the greatest influence on outcomes of primary and secondary CNS
lymphomas: The Lexington experience. Ann Hematol. 102:141–154.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bergner N, Monsef I, Illerhaus G, Engert A
and Skoetz N: Role of chemotherapy additional to high-dose
methotrexate for primary central nervous system lymphoma (PCNSL).
Cochrane Database Syst Rev. 11:CD0093552012.PubMed/NCBI
|
|
25
|
Wang CC, Carnevale J and Rubenstein JL:
Progress in central nervous system lymphomas. Br J Haematol.
166:311–325. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Barajas RF, Politi LS, Anzalone N, Schöder
H, Fox CP, Boxerman JL, Kaufmann TJ, Quarles CC, Ellingson BM, Auer
D, et al: Consensus recommendations for MRI and PET imaging of
primary central nervous system lymphoma: Guideline statement from
the International Primary CNS Lymphoma Collaborative Group (IPCG).
Neuro Oncol. 23:1056–1071. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Abla O, Weitzman S, Blay JY, O'Neill BP,
Abrey LE, Neuwelt E, Doolittle ND, Baehring J, Pradhan K, Martin
SE, et al: Primary CNS lymphoma in children and adolescents: a
descriptive analysis from the International Primary CNS Lymphoma
Collaborative Group (IPCG). Clin Cancer Res. 17:346–352. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bromberg JEC, Issa S, Bakunina K, Minnema
MC, Seute T, Durian M, Cull G, Schouten HC, Stevens WBC, Zijlstra
JM, et al: Rituximab in patients with primary CNS lymphoma (HOVON
105/ALLG NHL 24): A randomised, open-label, phase 3 intergroup
study. Lancet Oncol. 20:216–228. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luo W, Ji LH, Geng H, Ma XJ, Xiong H, Yin
QC, Yin YJ, Yu L and Ma J: Clinical therapeutic efficacy of
rituximab combined with methotrexate on primary central nervous
system lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 24:444–447.
2016.(In Chinese). PubMed/NCBI
|
|
30
|
Chen C, Sun P, Cui J, Yan S, Chen H, Xia
Y, Bi X, Liu P, Wang Y, Yang H, et al: High-dose Methotrexate plus
temozolomide with or without rituximab in patients with untreated
primary central nervous system lymphoma: A retrospective study from
China. Cancer Med. 8:1359–1367. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mou K, Gu WW, Gu CH and Qi JD: Curative
efficacy of high dose MTX combined with rituxan for treatment
primary CNS lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi.
25:1406–1409. 2017.(In Chinese). PubMed/NCBI
|
|
32
|
Sun X, Liu J, Wang Y, Bai X, Chen Y, Qian
J, Zhu H, Liu F, Qiu X, Sun S, et al:
Methotrexate-cytarabine-dexamethasone combination chemotherapy with
or without rituximab in patients with primary central nervous
system lymphoma. Oncotarget. 8:49156–49164. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Patekar M, Adhikari N, Biswas A, Raina V,
Kumar L, Mohanti BK, Gogia A, Sharma A, Batra A, Bakhshi S, et al:
Primary CNS Lymphoma in India: A 17-year experience from the all
India institute of medical sciences. J Global Oncol. 5:1–9. 2019.
View Article : Google Scholar
|
|
34
|
Pang DW, Chen FL, Guo HG, et al: Clinical
Efficacy of High Dose Methotrexate, Temozolomide and Rituximab in
the Treatment of Patients with Primary Central Nervous System
Lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 29:1175–1180.
2021.(In Chinese). PubMed/NCBI
|
|
35
|
Birnbaum T, Stadler EA, von Baumgarten L
and Straube A: Rituximab significantly improves complete response
rate in patients with primary CNS lymphoma. J Neuro Oncol.
109:285–291. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gregory G, Arumugaswamy A, Leung T, Chan
KL, Abikhair M, Tam C, Bajel A, Cher L, Grigg A, Ritchie D and Opat
S: Rituximab is associated with improved survival for aggressive B
cell CNS lymphoma. Neuro Oncol. 15:1068–1073. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Houillier C, Ghesquières H, Chabrot C,
Soussain C, Ahle G, Choquet S, Nicolas-Virelizier E, Bay JO,
Vargaftig J, Gaultier C, et al: Rituximab, methotrexate,
procarbazine, vincristine and intensified cytarabine consolidation
for primary central nervous system lymphoma (PCNSL) in the elderly:
A LOC network study. J Neuro Oncol. 133:315–320. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kansara R, Shenkier TN, Connors JM, Sehn
LH, Savage KJ, Gerrie AS and Villa D: Rituximab with high-dose
methotrexate in primary central nervous system lymphoma. Am J
Hematol. 90:1149–1154. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Holdhoff M, Ambady P, Abdelaziz A, Sarai
G, Bonekamp D, Blakeley J, Grossman SA and Ye X: High-dose
methotrexate with or without rituximab in newly diagnosed primary
CNS lymphoma. Neurology. 83:235–239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mocikova H, Pytlik R, Sykorova A, Janikova
A, Prochazka V, Vokurka S, Berkova A, Belada D, Campr V, Buresova
L, et al: Role of rituximab in treatment of patients with primary
central nervous system lymphoma: A retrospective analysis of the
Czech lymphoma study group registry. Leuk Lymphoma. 57:2777–2783.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hernández-Verdin I, Kirasic E, Wienand K,
Mokhtari K, Eimer S, Loiseau H, Rousseau A, Paillassa J, Ahle G,
Lerintiu F, et al: Molecular and clinical diversity in primary
central nervous system lymphoma. Ann Oncol. 34:186–199. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ostrom QT, Gittleman H, Xu J, Kromer C,
Wolinsky Y, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical
report: Primary brain and other central nervous system tumors
diagnosed in the united states in 2009–2013. Neuro Oncol. 18 (Suppl
5):v1–v75. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mata-Molanes JJ, Rebollo-Liceaga J,
Martínez-Navarro EM, Manzano RG, Brugarolas A, Juan M and Sureda M:
Relevance of Fc gamma receptor polymorphisms in cancer therapy with
monoclonal antibodies. Front Oncol. 12:9262892022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lee YH and Song GG: Association between
functional FCGR3A F158V and FCGR2A R131H polymorphisms and
responsiveness to rituximab in patients with autoimmune diseases: A
meta-analysis. Pharmacogenomics J. 23:210–216. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Murphy KE, Niederer HA, King KS, Harris
EC, Glass SM and Cox CJ: Accurate interrogation of FCGR3A rs396991
in European and Asian populations using a widely available TaqMan
genotyping method. Pharmacogenet Genomics. 25:569–572. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen S, Chen H and Xu S: Population
genomics insights into pharmacogenomic differentiation between east
asians and europeans. Clin Pharmacol Ther. 120:510–519. 2026.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pulido JS, Vierkant RA, Olson JE, Abrey L,
Schiff D and O'Neill BP: Racial differences in primary central
nervous system lymphoma incidence and survival rates. Neuro Oncol.
11:318–322. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhou X, Niu X, Li J, Zhang S, Yang W, Yang
Y, Mao Q and Liu Y: Risk Factors for early mortality in patients
with primary central nervous system lymphoma: A large-cohort
retrospective study. World Neurosurg. 138:e905–e912. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fox CP, Phillips EH, Smith J, Linton K,
Gallop-Evans E, Hemmaway C, Auer DP, Fuller C, Davies AJ, McKay P,
et al: Guidelines for the diagnosis and management of primary
central nervous system diffuse large B-cell lymphoma. Br J
Haematol. 184:348–363. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Song Y, Wen Y, Xue W, Zhang Y and Zhang M:
Effect of rituximab on primary central nervous system lymphoma: A
meta-analysis. Int J Hematol. 106:612–621. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang Y, Liu Z, Gao C, Bian H, Ma Y, Jing
F and Zhao X: Role of rituximab in treatment of patients with
primary central nervous system lymphoma (PCNSL): A systematic
review and meta-analysis. Clin Lymphoma Myeloma Leuk. 23:733–741.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Miyakita Y, Ohno M, Takahashi M, Muragaki
Y, Katai H and Narita Y: Immunochemotherapy using rituximab (RTX)
and high-dose methotrexate (HD-MTX): An evaluation of the addition
of RTX to HD-MTX in recurrent primary central nervous system
lymphoma (PCNSL). Jpn J Clin Oncol. 47:919–924. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Cook MR, Dorris CS, Makambi KH, Luo Y,
Munshi PN, Donato M, Rowley S, Saad A, Goy A, Dunleavy K and Ali A:
Toxicity and efficacy of CAR T-cell therapy in primary and
secondary CNS lymphoma: A meta-analysis of 128 patients. Blood Adv.
7:32–39. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bessone F and Björnsson ES: Drug-induced
liver injury due to biologics and immune check point inhibitors.
Med Clin North Am. 107:623–640. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Reddy KR, Beavers KL, Hammond SP, Lim JK
and Falck Ytter YT; American Gastroenterological Association
Institute, : American Gastroenterological Association Institute
guideline on the prevention and treatment of hepatitis B virus
reactivation during immunosuppressive drug therapy.
Gastroenterology. 148:215–219. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Athni TS and Barmettler S:
Hypogammaglobulinemia, late-onset neutropenia, and infections
following rituximab. Ann Allergy Asthma Immunol. 130:699–712. 2023.
View Article : Google Scholar : PubMed/NCBI
|
